Skip to main content
Premium Trial:

Request an Annual Quote

You Can't Be Too Careful

Daniel MacArthur at Genetic Future blogs about a new "inquiry into personalised medicine" started by the Nuffield Council on Bioethics, a British think tank. "Such inquiries seem to be popping up like mushrooms these days - for instance, the UK House of Lords has an inquiry into Genomic Medicine that I gather is due to report at some point in the next few weeks," he writes.

MacArthur says the "comparatively socialist" British healthcare system is likely a large factor in this trend. "Discussion of personalised medicine creates a particular tension here on top of the usual fears about genohype: if patients reeling from the results of a genome scan end up chewing through unnecessary extra medical appointments, the taxpayer will foot the bill, and an already highly strained public system will have to cope with an additional load," MacArthur blogs.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.